Want to join the conversation?
A retrospective analysis of the iPro2 Professional CGM from $MDT demonstrated that patients with type 2 diabetes experience high rates of glycemic variability, hypoglycemia and hyperglycemia regardless of whether they manage their diabetes with diet/exercise, oral medication or insulin.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.